Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMIYAMOTO, D.
dc.contributor.authorSOTTO, M. N.
dc.contributor.authorOTANI, C. S. V.
dc.contributor.authorFUKUMORI, L. M. I.
dc.contributor.authorPEREIRA, N. V.
dc.contributor.authorSANTI, C. G.
dc.contributor.authorMARUTA, C. W.
dc.contributor.authorBURNIER, M. N. N.
dc.contributor.authorREBEIS, M. M.
dc.contributor.authorAOKI, V.
dc.date.accessioned2017-04-07T15:06:48Z
dc.date.available2017-04-07T15:06:48Z
dc.date.issued2017
dc.description.abstractBackground Erythroderma is a clinical skin syndrome shared by patients with cutaneous disorders of distinct aetiologies as a result of the combined actions of chemokines, adhesion molecules, and cytokines, such as vascular endothelial growth factor (VEGF). Objective To evaluate the profile of serum levels of VEGF and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) in pemphigus foliaceus (PF) patients with erythroderma. Methods We conducted a retrospective study, which included (i) a chart review of all PF patients from the Autoimmune Blistering Clinic, University of Sao Paulo, Brazil, from January 1991 to December 2014, together with an evaluation of demographic variables, hospitalization duration and complications and (ii) analysis of the circulating VEGF and sVEGFR-1 levels in PF patients with erythroderma by ELISA. The controls included patients with pemphigus vulgaris or psoriasis. Results We observed higher serum VEGF levels in PF patients during erythroderma than during the non-erythrodermic phase. PF patients showed increased serum levels of sVEGFR-1 during the erythrodermic phase in comparison to controls. Interestingly, the sVEGFR-1 and antidesmoglein-1 levels were positively correlated during the non-erythrodermic period. Conclusion Erythroderma, which represents one clinical form of PF, implies more severe outcomes. The circulating levels of VEGF, a potent endothelial activator, are increased in PF patients with erythroderma; this result suggests the contribution of the blood vessel endothelium to the pathogenesis of this clinical syndrome. Interestingly, our findings showed a positive correlation between the sVEGFR-1 and antidesmoglein-1 antibody levels, indicating a suppressive response to VEGF augmentation during the erythrodermic phase of PF.
dc.description.indexMEDLINE
dc.description.sponsorshipFUNADERSP
dc.description.sponsorshipCNPq [444547/2014-2]
dc.identifier.citationJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.31, n.2, p.333-336, 2017
dc.identifier.doi10.1111/jdv.13905
dc.identifier.eissn1468-3083
dc.identifier.issn0926-9959
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/18809
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofJournal of the European Academy of Dermatology and Venereology
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subject.otherfactor receptor-1
dc.subject.otherexpression
dc.subject.otherdermatitis
dc.subject.othervegf
dc.subject.otherherpetiformis
dc.subject.otherangiogenesis
dc.subject.otherhyperplasia
dc.subject.otherpsoriasis
dc.subject.othervulgaris
dc.subject.otherselectin
dc.subject.wosDermatology
dc.titleIncreased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalBURNIER, M. N. N.:McGill Univ, Montreal, PQ, Canada
hcfmusp.citation.scopus11
hcfmusp.contributor.author-fmusphcDENISE MIYAMOTO
hcfmusp.contributor.author-fmusphcMIRIAN NACAGAMI SOTTO
hcfmusp.contributor.author-fmusphcCAMILA SAYURI VICENTINI OTANI
hcfmusp.contributor.author-fmusphcLIGIA MARIA ICHIMURA FUKUMORI
hcfmusp.contributor.author-fmusphcNAIURA VIEIRA PEREIRA
hcfmusp.contributor.author-fmusphcCLAUDIA GIULI SANTI
hcfmusp.contributor.author-fmusphcCELINA WAKISAKA MARUTA
hcfmusp.contributor.author-fmusphcMARINA MATTOS REBEIS
hcfmusp.contributor.author-fmusphcVALERIA AOKI
hcfmusp.description.beginpage333
hcfmusp.description.endpage336
hcfmusp.description.issue2
hcfmusp.description.volume31
hcfmusp.origemWOS
hcfmusp.origem.pubmed27510449
hcfmusp.origem.scopus2-s2.0-84992445987
hcfmusp.origem.wosWOS:000393573600019
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAmeglio F, 1997, J BIOL REG HOMEOS AG, V11, P148
hcfmusp.relation.referenceBae ON, 2015, BIOMOL THER, V23, P12, DOI 10.4062/biomolther.2014.102
hcfmusp.relation.referenceBROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974
hcfmusp.relation.referenceCreamer D, 1996, LANCET, V348, P1101, DOI 10.1016/S0140-6736(05)64447-9
hcfmusp.relation.referenceElias PM, 2008, AM J PATHOL, V173, P689, DOI 10.2353/ajpath.2008.080088
hcfmusp.relation.referenceFerrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
hcfmusp.relation.referenceFlisiak I, 2010, CYTOKINE, V52, P225, DOI 10.1016/j.cyto.2010.09.012
hcfmusp.relation.referenceJames KA, 2011, DERMATOL CLIN, V29, P405, DOI 10.1016/j.det.2011.03.012
hcfmusp.relation.referenceJoly P, 2011, CLIN DERMATOL, V29, P432, DOI 10.1016/j.clindermatol.2011.01.013
hcfmusp.relation.referenceKunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964
hcfmusp.relation.referenceLehman JS, 2011, DERMATOL CLIN, V29, P591, DOI 10.1016/j.det.2011.06.021
hcfmusp.relation.referenceOzmen A, 2016, BIOTECH HISTOCHEM, V91, P296, DOI 10.3109/10520295.2016.1161234
hcfmusp.relation.referencePal S, 1998, INT J DERMATOL, V37, P104
hcfmusp.relation.referenceRuffini F, 2011, BRIT J DERMATOL, V164, P1061, DOI 10.1111/j.1365-2133.2010.10200.x
hcfmusp.relation.referenceSamorano-Lima LD, 2014, INT J DERMATOL, V53, P685, DOI 10.1111/j.1365-4632.2012.05818.x
hcfmusp.relation.referenceSehgal VN, 2004, INT J DERMATOL, V43, P39, DOI 10.1111/j.1365-4632.2004.01975.x
hcfmusp.relation.referenceShibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
hcfmusp.relation.referenceSigurdsson V, 2000, J CUTAN PATHOL, V27, P436, DOI 10.1034/j.1600-0560.2000.027009436.x
hcfmusp.relation.referenceWeiss D, 2015, ACTA DERM-VENEREOL, V95, P559, DOI 10.2340/00015555-2023
hcfmusp.relation.referenceYang KY, 2011, CRIT CARE, V15, DOI 10.1186/cc9412
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication9298564f-de32-4534-a058-e59872735de2
relation.isAuthorOfPublicationa7e1ee53-9c53-461a-b330-4410b8de96f9
relation.isAuthorOfPublication574e4e4a-2983-4547-aff4-4ec34d8f6b49
relation.isAuthorOfPublication38154dc9-ccdc-4792-b9af-dbccc6549f5a
relation.isAuthorOfPublicationd169e8df-23ca-4852-ab8b-a3c093020435
relation.isAuthorOfPublication95eafa3a-94ea-4de1-ba37-426c1b6f1f61
relation.isAuthorOfPublication2af23e04-c9af-4f35-bd14-4c93e9831d29
relation.isAuthorOfPublicationfb1dd89d-da51-4556-b789-25bfbe612723
relation.isAuthorOfPublication39977d9c-4d58-4ad3-9df5-f4625a05e3b3
relation.isAuthorOfPublication.latestForDiscovery574e4e4a-2983-4547-aff4-4ec34d8f6b49
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MIYAMOTO_Increased_serum_levels_of_vascular_endothelial_growth_factor_2017.PDF
Tamanho:
94.82 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56